IL-2 expansion of T and NK cells from growth factor-mobilized peripheral blood stem cell products: Monocyte inhibition

Journal of Immunotherapy

Volumn 21, Issue 6, 1998, Pages 409-417

  Ageitos, Ana G ^a   Singh, Rakesh K ^a   Ino, Kazuhiko ^a   Ozerol, Ibrahim ^a   Tarantolo, Stefano ^a   Reed, Elizabeth K ^a   Talmadge, James E ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Immunophenotype; Interleukin 2; Monocytes; Natural killer cells; Suppression; T cells; Tolerance

Indexed keywords

CARBONYL IRON; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; RECOMBINANT INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; BREAST CANCER; CONTROLLED STUDY; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOTOXICITY; MITOGENESIS; MONONUCLEAR CELL; NATURAL KILLER CELL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0031759379     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199811000-00002     Document Type: Article

References (54)

1. Kessinger A, Bierman PJ, Vose JM, Armitage JO. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin’s disease. Blood 1991;77:2322-5.
2. Vose JM, Armitage J, Kessinger A. High dose chemotherapy and autologous transplant with peripheral blood stem cells. Oncology 1993;7:23.
3. To LB, Roberts M, Haylock D. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992;9:277-84.
4. Kessinger A. Circulating stem cells: waxing hematopoietic. N Engl J Med 1995;333:315.
5. Henon PR, Liang H, Beck-Wirth G, et al. Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplant 1992;9: 285-91.
6. Roberts MM, To LB, Gillis D, et al. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation. Bone Marrow Transplant 1993;12:469-75.
7. Talmadge JE, Reed E, Ino K, et al. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplant 1997;19:161-72.
8. Ashihara E, Shimazaki C, Yamagata N, et al. Reconstitution of lymphocyte subsets after peripheral blood stem cell transplantation: two color cytometric analysis. Bone Marrow Transplant 1994;13:377-81.
9. Foot ABM, Potter MN, Donaldson C, et al. Immune reconstitution after BMT in children. Bone Marrow Transplant 1993;11:7-13.
10. Atkinson K. Reconstitution of the hematopoietic and immune recovery systems after human marrow transplantation. Bone Marrow Transplant 1990;5:209-26.
11. Talmadge JE, Reed EC, Kessinger A, et al. Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation. Bone Marrow Transplant 1996; 17: 101-9.
12. Verma UN, Areman E, Dickerson SA, Kotula PL, Sacher R, Mazumder A. Interleukin-2 activation of chemotherapy and growth factor-mobilized peripheral blood stem cells for generation of cytotoxic effectors. Bone Marrow Transplant 1995;15:199-206.
13. Meehan KR, Verma UN, Rajogopal C, Cahill R, Frankel S, Mazumder A. Stem cell transplantation with chemoradiotherapy myeloablation and interleukin-2. J Infus Chemother 1996;6:28-32.
14. Areman EM, Mazumder A, Kotula PL, et al. Hematopoietic potential of IL-2-cultured peripheral blood stem cells from breast cancer patients. Bone Marrow Transplant 1996;18:521-5.
15. Ageitos AG, Ino K, Ozerol I, Tarantolo S, Talmadge JE. Restoration of immune function in mobilized stem cell product by suppressor cell removal. Bone Marrow Transplant 1997;20:117-23.
16. Singh RK, Varney ML, Ageitos AG, Heimann D, Ino K. Differention cytokine expression in growth factor mobilized peripheral stem cell and bone marrow products and their immunoregulatory significance [Abstract]. Proc Am Assoc Cancer Res 1997;58:33.
17. Mills KC, Gross TG, Varney ML, et al. Immunologic phenotype and function in human bone marrow, blood stem cells and umbilical cord blood. Bone Marrow Transplant 1996;18:53-61.
18. Ino K, Singh RK, Talmadge JE. Monocytes from mobilized stem cells inhibit T cell function. J Leukocyte Biol 1997;61:583-91.
19. Taguchi K, Shibuya A, Inazawa Y, Abe T. Suppressive effect of granulocyte-macrophage colony-stimulating factor on the generation of natural killer cells in vitro. Blood 1990;79:3227-32.
20. Triozzi PL, Tucker F, Benzies T, Balcerzak SP. Antitumor and accessory immune activities of peripheral blood stem cells mobilized granulocyte-macrophage colony-stimulating factor. Bone Marrow Transplant 1996;18:47-52.
21. Dennis MW. Ingestion of carbonyl iron. In: Herscowitz HB, Holden HT, Bellanti JA, Ghaffar A, eds. Manual of macrophage methodology, collection, characterization and function. New York: Dekker, 1981; 105-11.
22. Wang SY, Su CY, Hsu ML, Chen LY, Tzeng CH. Effect of lipopolysaccharide on the production of colony-stimulating factors by the stromal cells in long-term bone marrow culture. Exp Hematol 1991;19:122-7.
23. Herberman RB, Hiserodt J, Vujanovic N, et al. Most lymphokine-activated killer (LAK) activity mediated by blood and splenic lymphocytes is attributable to stimulation of natural killer cells by interleukin-2. Immunol Today 1987;8:178.
24. Hiserodt JC. Lymphokine-activated killer cells: biology and relevance to disease. Cancer Invest 1993;11:420-39.
25. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995;13:399-415.
26. Dilloo D, Laws H, Hanenberg H, Korholz D, Nurnberger W, Burdach S. Induction of two distinct natural killer cell populations, activated T cells and antineoplastic cytokines, by interleukin-2 therapy in children with solid tumors. Exp Hematol 1994;22:1081-8.
27. Spits H, Lanier LL, Phillips JH. Development of human T and natural killer cells. Blood 1995;85:2654-70.
28. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988;240:1169.
29. Pierson BA, Europa AF, Hu W, Miller JS. Production of human natural killer cells for adoptive immunotherapy using a computercontrolled stirred-tank bioreactor. J Hematother 1996;5:475-83.
30. Miller JS, Oelkers S, Verfaillie C, et al. Role of monocytes in the expression of human activated natural killer cells. Blood 1992;80: 2221.
31. Sone S, Utsugi T, Nii A, Ogura T. Effects of human alveolar macrophages on the induction of lymphokine (IL-2) activated killer cells. J Immunol 1987;139:29-34.
32. Nii A, Sone S, Utsugi T, Yanagawa H, Ogura T. Up and down regulation of human lymphokine-activated killer cell induction by monocytes, depending on their functional state. Int J Cancer 1988;41:33-40.
33. 2-receptors. Scand J Immunol 1991;34:741-52.
34. Krakauer T. A macrophage-derived factor that inhibits the production and action of interleukin 2. J Leukocyte Biol 1985;38:429-39.
35. + cells in cancer patients receiving recombinant interleukin-2. Cancer Res 1988;48:6597-602.
36. + killer cells. Blood 1995;86:3493-9.
37. Rosenberg SA, Lotze MT. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu Rev Immunol 1986;4:681-709.
38. Lissoni P, Barni S, Tancini G, et al. A randomized study with subcutaneous low-dose interleukin-2 alone vs. interleukin-2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br J Cancer 1994;69:196-9.
39. Farace F, Pallardy M, Angevin E, Hercend T, Escudier B, Triebel F. Metastatic renal cell carcinoma patients treated with interleukin-2 or interleukin-2 plus interferon gamma: immunological monitoring. Int J Cancer 1994;57:814-21.
40. Raspadori D, Lauria F, Ventura MA, et al. Low doses of rIL-2 after autologous bone marrow transplantation induce a “prolonged” immunostimulation of NK compartment in high-grade non-Hodgkin’s lymphomas. Ann Hematol 1995;71:175-9.
41. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer-cell phenomenon: lysis of natural-killer resistant fresh solid tumor cells by interleukin-2-activated autologous human peripheral-blood lymphocytes. J Exp Med 1982;155:1823-41.
42. Silva MR, Parreira A, Ascensao JL. Natural killer cell numbers and activity in mobilized peripheral blood stem cell grafts: conditions for in vitro expansion. Exp Hematol 1995;23:1676-81.
43. Nakarai T, Robertson MJ, Streuli M, et al. Interleukin 2 receptor gamma chain expression on resting and activated lymphoid cells. J Exp Med 1994;180:241-51.
44. Smith KA. Lowest dose interleukin-2 immunotherapy. Blood 1983;81:1414-23.
45. Caligiuri MA, Zmuidzinas A, Manley TJ, Levin H, Smith KA, Ritz J. Functional consequences of IL-2 receptor expression on resting human lymphocytes: identification of a novel NK-cell sub-set with high-affinity receptors. J Exp Med 1990;171:1509-26.
46. Weil-Hillman G, Voss SD, Fisch P, et al. Natural killer cells activated by interleukin-2 treatment in vivo respond to IL-2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype. Cancer Res 1990;50:2683-91.
47. Phillips JH, Takeshita T, Sugamura K, Lanier LL. Activation of natural killer cells via the p75 interleukin receptor. J Exp Med 1989;170:170-91.
48. Cantrell DA, Smith KA. Transient expression of interleukin-2 receptors: consequences for T-cell growth. J Exp Med 1983; 158:1895.
49. Timonen T, Ortaldo JR, Herberman RB. Characteristics of human large granular lymphocytes and relationship to natural killer and NK cells. J Exp Med 1981; 153:569.
50. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989;47:187.
51. + cells in bone marrow transplant recipients. Bone Marrow Transplant 1990;5:259-64.
52. + natural killer cells after bone marrow transplantation. Blood 1992;79:3239-44.
53. Benyunes MC, Higuchi C, York A, et al. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial. Bone Marrow Transplant 1995;16:283-8.
54. Miller JS, Klingsporn S, Lund J, Perry EH, Verfaillie C, McGlave P. Large scale ex vivo expansion and activation of human natural killer cells for autologous therapy. Bone Marrow Transplant 1994;14:555-62.